FWM
TXG icon

Focused Wealth Management’s 10x Genomics TXG Stock Holding History

Focused Wealth Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-400
Closed -$16.5K – 1102
2023
Q3 		$16.5K Hold
400
– – ﹤0.01% 458
2023
Q2 		$22.3K Hold
400
– – ﹤0.01% 420
2023
Q1 		$22.3K Hold
400
– – ﹤0.01% 433
2022
Q4 		$14.6K Sell
400
-2,355
-85% -$77K ﹤0.01% 473
2022
Q3 		$78K Sell
2,755
-135
-5% -$5.14K 0.02% 207
2022
Q2 		$131K Sell
2,890
-60
-2% -$3.11K 0.02% 165
2022
Q1 		$224K Buy
2,950
+15
+0.5% +$1.31K 0.04% 145
2021
Q4 		$437K Sell
2,935
-40
-1% -$6.13K 0.07% 107
2021
Q3 		$433K Sell
2,975
-190
-6% -$32.6K 0.07% 106
2021
Q2 		$620K Sell
3,165
-90
-3% -$16.3K 0.1% 84
2021
Q1 		$589K Buy
3,255
+155
+5% +$26.8K 0.1% 90
2020
Q4 		$439K Buy
+3,100
New +$450K 0.09% 102

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Focused Wealth Management's TXG Position: Q4 2023 in Review

Focused Wealth Management sold out of 10x Genomics (TXG) in Q4 2023, closing a stake of 400 shares — an estimated $16.5K sold.

Focused Wealth Management first reported a position in TXG in Q4 2020 and held it in 12 quarters. The position peaked at $620K in Q2 2021. 275 funds tracked by Wall St. Rank hold TXG as of Q4 2023.

  • Focused Wealth Management reported no remaining 10x Genomics position as of Q4 2023 after selling out during the quarter.
  • Focused Wealth Management sold 400 10x Genomics shares in Q4 2023, an estimated $16.5K.
  • Focused Wealth Management first reported a position in 10x Genomics in Q4 2020 and held it in 12 quarters.
  • Focused Wealth Management's 10x Genomics position peaked at $620K in Q2 2021.
  • 275 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2023.

Based on Focused Wealth Management's 13F filing for Q4 2023, filed 10 Jan 2024.